title: Teriparatide for postmenopausal osteoporosis.
abstract: Teriparatide (Forsteo - Eli Lilly) is the first parathyroid hormone derivative to be licensed for the treatment of women with postmenopausal osteoporosis. It is described as a "bone-formation agent", in contrast to established treatments, such as bisphosphonates, raloxifene, calcitriol and calcitonin, which reduce bone resorption. Here we consider whether teriparatide offers any worthwhile advantages over these other options.
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D016527:Drug Costs; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012516:Osteosarcoma / Q000139:chemically induced; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D004164:Diphosphonates; D004338:Drug Combinations; D019379:Teriparatide